Corona Remedies is a branded-pharmaceuticals house that sells prescription medicines almost entirely inside India - roughly 96 of every 100 rupees it earns come from the domestic market. Founded in 2004 in Ahmedabad by two brothers who had spent their early careers at Bayer and Novartis, the company has spent two decades deliberately pivoting from short-course acute medicines to long-duration chronic therapies, so that by FY26 nearly three-quarters of its sales were in chronic and sub-chronic care. The recurring approach that explains everything else is a “buy, build and scale” playbook: acquire established brands from multinationals, plug them into a specialist-doctor sales force that is skewed toward higher-prescribing physicians, and then grow them faster than the market by driving volume, price and new launches all at once. # Business segments A single engine - branded domestic formulations - run through a specialist-doctor sales force, with a small international B2B sidecar and a dedicated women’s-hormone manufacturing base that just came on stream. ## 1. Branded domestic formulations: a chronic-care house for India’s specialist doctors **Corona sells 76 prescription brands into four chronic therapy areas, reaching over 180,000 doctors through a field force that deliberately targets specialists and super-specialists rather than general practitioners.** - **Skewed toward the doctors who write the most prescriptions** - super-specialists and specialists together generate 67% of Corona’s prescriptions, compared with 43% for the industry as a whole, while general practitioners account for only 26% versus the industry’s 39%. That is how a mid-sized company extracts higher productivity from each sales call. - **Thirty-two engine brands do the heavy lifting** - of the 76 brands in the portfolio, 32 are designated “Engine Brands” and they contribute roughly three-quarters of domestic sales, having grown at a compound rate of about 17-19% over the three years to March 2026. The top ten brands alone bring in half of all revenue. - **Chronic therapies mean recurring demand** - women’s healthcare, cardio-diabeto, pain management and urology together made up 71.9% of domestic sales in FY26, so the business is built on medicines patients take for months or years rather than a few days. Low exposure to the government’s essential-medicines price list - just under 10% of sales - further insulates the portfolio from sudden price cuts. - **Growth comes from three levers, all running ahead of the market** - volume growth of 3.0% (more than four times the industry’s 0.7%), price growth of 7.8% (1.4 times the industry), and new-product growth of 6.4% (2.6 times the industry). The company launched 13 to 15 new products in FY26 alone, all within its chosen therapy areas. - **Geographic spread is evening out** - a decade ago the East Zone contributed 66.2% of domestic sales; by FY26 that had fallen to 45.2%, with the South, North and West zones each climbing to between 14% and 20.8%, so the growth is no longer tied to one region. ## 2. Women’s healthcare and infertility: the largest therapy, now with its own factory **Women’s healthcare is Corona’s biggest single therapy area - 30 mother brands, a number-five ranking in the Indian market, and growth at nearly three times the category rate - and it is the beachhead for a push into infertility treatments.** - **The therapy has outgrown the market by a wide margin** - women’s healthcare sales reached INR 488.1 crore in the twelve months to March 2026, expanding at a 20.3% compound rate against the IPM’s 7.1%. That is a 2.9-times multiplier on the category. - **Biosimilars opened the infertility door** - in FY26 the company entered the biosimilars and infertility segment and launched 15 products, marking its entry into biologics and creating a dedicated IVF taskforce as a fourth focus theme within women’s health. - **Acquisitions filled the pipeline quickly** - Corona bought a portfolio of seven brands from Bayer Zydus and separately acquired Wokadine (the number-two povidone-iodine brand in India, with a 46-year legacy) from Dr. Reddy’s, both paid for entirely from internal cash. The Bayer brands were re-launched in the second half of FY26 to deepen the infertility footprint. - **A dedicated hormone plant just started production** - on 30 June 2026 a new EU-GMP-approved women’s-hormone facility in Bhayla, Ahmedabad, began commercial output with capacity for 194 million tablets or capsules and 1.5 million ointments or gels a year, raising in-house hormone capacity by nearly 20%. The plant is designed to serve both domestic and export orders. ## 3. Brand acquisitions and in-licensing: the buy-and-scale engine **Corona repeatedly buys established brands from multinationals - GSK, Abbott, Sanofi, Bayer, Dr. Reddy’s - and then accelerates their growth by routing them through its specialist sales force.** - **Bought, not just built** - the acquisition roster includes Dilo and Stelbid from GSK, Thyrocab and Obimet from Abbott, Myoril from Sanofi, seven infertility brands from Bayer Zydus, and Wokadine from Dr. Reddy’s. Each deal was funded from internal accruals, so the company carries no acquisition debt for them. - **The playbook works on the numbers** - brands acquired from GSK grew at a 36.5% compound rate from acquisition to March 2026, while the Abbott-acquired brands Obimet, Triobimet and Thyrocab grew at 16.8% over the same stretch. The acquired brands get plugged into the same specialist-doctor detailing engine that drives the rest of the portfolio. - **In-licensing adds molecules without the R&D lead time** - an arrangement with Ferring Pharmaceuticals of Switzerland covers certain women’s-health and urology products; Corona is one of only three Indian companies to have in-licensed any brand from Ferring. # Manufacturing and quality infrastructure **Corona runs three plants - two for oral solids and one dedicated to women’s hormones - with about two-thirds of sales made in-house and the rest outsourced.** - **Two legacy plants, recently expanded** - the Bhayla (Gujarat) facility can produce roughly 1.25 billion tablets or capsules and 20 million sachets a year, and the Solan (Himachal Pradesh) plant adds another 403 million tablets or capsules and 10 million liquid bottles. An additional 400-million-tablet line at Bhayla began production in December 2025, paid for from internal cash. - **The new hormone plant completes the triad** - commissioned in June 2026, the Bhayla hormone facility adds 194 million tablets or capsules and 1.5 million ointments or gels of annual capacity, purpose-built for women’s-health products and certified to EU-GMP standards. - **Regulatory certifications are the passport to exports** - the Gujarat plant holds WHO-GMP and EAEU-GMP approvals, and the EAEU certification obtained in January 2026 unlocks five Eurasian markets - Russia, Kyrgyzstan, Armenia, Belarus and Kazakhstan - with a combined pharmaceutical market of up to roughly USD 25 billion. # Group structure and partners **Corona Remedies is the listed parent, with a strategic stake in a hormone-API maker and a Swiss in-licensing tie-up that secures key raw materials and products.** - **Backward integration through an associate** - Corona holds an equity-method investment valued at INR 26.1 crore in La Chandra Pharmalabs Private Limited, which runs an EU-GMP and WHO-GMP-certified hormonal API plant in Palanpur, Gujarat. La Chandra supplies specified hormone APIs to Corona under a right-of-first-refusal arrangement, reducing the risk of supply disruption for the women’s-health portfolio. - **Ferring in-licensing** - the agreement with Ferring Pharmaceuticals of Switzerland covers select women’s-health and urology products, and Corona is one of only three Indian firms to hold such a licence from Ferring. - **Founder-led governance** - the board is chaired by Dr. Kirtikumar Mehta, with brothers Nirav Mehta (Managing Director and CEO) and Ankur Mehta (Joint Managing Director) running day-to-day operations, supported by four independent directors and a senior management team that includes presidents for India business, commercial operations and global business.